The Worldwide Insulin Pen Industry is Expected to Reach $64.7 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Insulin Pen Market, Users, Global Forecast 2023-2027, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis” report has been added to ResearchAndMarkets.com’s offering.

This report provides a detailed analysis of Global Insulin Pen Industry, the global insulin pump market is estimated to reach US$ 64.75 Billion by 2027, US$ 50.84 Billion in 2021.

Companies Mentioned

B. Braun Melsungen AG

Eli Lilly and Company

Becton, Dickinson(BD)

Novo Nordisk A/S

Ypsomed AG

Terumo Corporation

An insulin pen is a device that administers insulin to diabetic individuals. Patients with type 1 diabetes choose to use it for therapy, making it easy to inject insulin into the body. Insulin pen needles are thinner and shorter than those used in syringes. It also gives more exact dosing and less pain than vials and syringes, and clinicians and patients prefer it. Furthermore, the insulin pen improves the quality of life and minimizes the dread of hyperglycaemia. The low cost of an insulin pen makes it more accessible to people of all ages. However, insulin pens should not be shared since infections like hepatitis can be transmitted.

Major Market Trends Shaping the Insulin Pen Market Worldwide:

With the high base of the aging population, which causes diabetes, the global insulin pen market has the enormous potential over time. As a result, manufacturers are concentrating their measures on the Asian market to meet the demand for insulin pen devices. The rising prevalence of diabetes among people of various ages is a major factor driving the global insulin pen market.

In addition, the insulin pen industry is benefiting from increased R&D activity. However, concerns over infusion pen safety and strict regulations for new product development are limiting the expansion of the insulin pen business. As a result, Global Insulin Pen Market Size is dexpanding with a CAGR Of 5.18% During 2022-2027.

COVID-19 Impact Analysis on Global Insulin Pen Industry:

According to the IDF, people with diabetes were more likely to acquire COVID-19 disease and have severe symptoms. As a result, demand for insulin pens use soared during the COVID-19 pandemic. As a result, the homecare insulin pen business exploded worldwide due to the epidemic. Furthermore, demand for automated and efficient insulin pens soared throughout the epidemic.

Segment Analysis in Global Insulin Pen Market:

The Global Insulin Pump Market is studied in the United States, United Kingdom, Israel, Germany, Netherlands, Sweden, France, Switzerland, Australia, Japan, Canada, Kuwait, Saudi Arabia, Italy, and Spain. Further, the market in detail is categorized based on Diabetes Population (Type 1 and Type 2), Insulin Pump Market Analysis (Insulin Pump User (Type 1 and Type 2) & Insulin Pump Market (Type 1 and Type 2)), and Reimbursement Policies on Insulin Pump.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Global Insulin Pen Analysis

5.1 Market

5.2 User

6. Global Insulin pen Market & Volume Share Analysis

6.1 Market share

6.1.1 Types

6.1.2 Country

6.2 Volume Share

6.2.1 Insulin Pen Users

7. By Types – Global Insulin Pen Market Analysis

7.1 Disposable Insulin Pen

7.2 Reusable Insulin Pen

7.3 Smart Insulin Pen

7.4 Insulin Pen Needle

8. United States

9. India

10. China

11. Brazil

12. Saudi Arabia

13. United Kingdom

14. Germany

15. Netherlands

16. Sweden

17. Switzerland

18. Australia

19. Company Analysis

For more information about this report visit https://www.researchandmarkets.com/r/of05xr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.